DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability ofDAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of

Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research

DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of its Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS)—a next-generation antibody designed to deliver superior reproducibility, specificity, and performance in retinal ganglion cell (RGC) research.

Developed under the PhosphoSolutions brand, the recombinant Guinea Pig RBPMS Antibody continues a legacy of high-performance neuroscience reagents while benefiting from Antibodies Inc.’s expanded validation, manufacturing, and global distribution infrastructure. This new recombinant mAb replaces the formerly available guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS).

RBPMS (RNA Binding Protein with Multiple Splicing) has emerged as the gold-standard marker for identifying retinal ganglion cells, supporting accurate cell identification and quantification in vision and neurodegeneration research. While guinea pig polyclonal antibodies have historically been valuable for multiplex immunofluorescence, traditional formats are limited by lot-to-lot variability and finite supply.

Our Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) addresses these limitations through recombinant engineering, eliminating lot-to-lot variability and supply constraints. The antibody combines the well-validated antigen-binding region of the OTI3B7 clone with a guinea pig IgG constant region, enabling efficient multiplexing alongside mouse and rabbit antibodies while delivering long-term consistency.

Key benefits include:

  • Recombinant RBPMS Antibody for retinal ganglion cell identification
  • Guinea Pig format for advanced multiplex immunolabeling
  • Clone OTI3B7-GP with defined amino acid sequence
  • Animal-free, serum-free production
  • Lot-to-lot reproducibility for longitudinal and multi-site studies

The antibody has been validated for immunohistochemistry (IHC) and Western blotting, providing clear and specific labeling of retinal ganglion cells in mammalian tissue samples.

The launch further reflects Antibodies Inc.’s commitment to supporting scientific discovery through a growing portfolio of specialized research brands.

Related Resources:
Explore the full PhosphoSolutions product line:
https://www.antibodiesinc.com/collections/phosphosolutions

Recombinant Guinea Pig RBPMS Antibody Product page:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-recombinant-antibody-oti3b7-gp-1834-rbpms

Researchers seeking alternative host species can also access the Rabbit Polyclonal RBPMS Antibody:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-1830-rbpms

Learn more about the Antibodies Inc. family of brands:
https://www.antibodiesinc.com/pages/our-brands

Available Now
The Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP, 1834-RBPMS) is available now through Antibodies Inc. and authorized global distributors.

About Antibodies Inc.
Antibodies Inc. provides researchers worldwide with rigorously validated antibodies, recombinant proteins, ELISA kits, and custom services. Through a growing portfolio of specialized brands—including PhosphoSolutions—Antibodies Inc. delivers reproducible tools that accelerate discovery across neuroscience, cell biology, and translational research.

Cision View original content:https://www.prnewswire.com/news-releases/antibodies-inc-launches-recombinant-guinea-pig-rbpms-antibody-oti3b7-gp-for-reproducible-retinal-research-302666278.html

SOURCE Antibodies Inc.

Market Opportunity
Graphite Logo
Graphite Price(GP)
$0.5623
$0.5623$0.5623
-3.81%
USD
Graphite (GP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Is Putnam Global Technology A (PGTAX) a strong mutual fund pick right now?

Is Putnam Global Technology A (PGTAX) a strong mutual fund pick right now?

The post Is Putnam Global Technology A (PGTAX) a strong mutual fund pick right now? appeared on BitcoinEthereumNews.com. On the lookout for a Sector – Tech fund? Starting with Putnam Global Technology A (PGTAX – Free Report) should not be a possibility at this time. PGTAX possesses a Zacks Mutual Fund Rank of 4 (Sell), which is based on various forecasting factors like size, cost, and past performance. Objective We note that PGTAX is a Sector – Tech option, and this area is loaded with many options. Found in a wide number of industries such as semiconductors, software, internet, and networking, tech companies are everywhere. Thus, Sector – Tech mutual funds that invest in technology let investors own a stake in a notoriously volatile sector, but with a much more diversified approach. History of fund/manager Putnam Funds is based in Canton, MA, and is the manager of PGTAX. The Putnam Global Technology A made its debut in January of 2009 and PGTAX has managed to accumulate roughly $650.01 million in assets, as of the most recently available information. The fund is currently managed by Di Yao who has been in charge of the fund since December of 2012. Performance Obviously, what investors are looking for in these funds is strong performance relative to their peers. PGTAX has a 5-year annualized total return of 14.46%, and is in the middle third among its category peers. But if you are looking for a shorter time frame, it is also worth looking at its 3-year annualized total return of 27.02%, which places it in the middle third during this time-frame. It is important to note that the product’s returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund’s [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund’s performance, it…
Share
BitcoinEthereumNews2025/09/18 04:05
QNT Technical Analysis Jan 21

QNT Technical Analysis Jan 21

The post QNT Technical Analysis Jan 21 appeared on BitcoinEthereumNews.com. QNT’s MACD histogram showing a positive trend and RSI stabilizing in the neutral zone
Share
BitcoinEthereumNews2026/01/21 23:54
SHIB Alert: First Three-Hour Death Cross Flashes on Chart in 2026, Is It Important?

SHIB Alert: First Three-Hour Death Cross Flashes on Chart in 2026, Is It Important?

The post SHIB Alert: First Three-Hour Death Cross Flashes on Chart in 2026, Is It Important? appeared on BitcoinEthereumNews.com. Shiba Inu is forming a death cross
Share
BitcoinEthereumNews2026/01/22 00:26